1028TiP ARC-12: Phase I/Ib dose escalation and dose expansion study to evaluate the safety and tolerability of AB308 + zimberelimab (AB122) in advanced malignancies

Abstract

PD-(L)1 inhibitors provide durable clinical benefit for some patients with various tumors; however, combination immune therapy may be needed to optimize outcomes. T-cell Immunoglobulin and ITIM domain (TIGIT), expressed on activated T and natural killer (NK) cells, inhibits antitumor immunity upon binding CD155 on tumors. AB308, an anti-TIGIT humanized IgG1 monoclonal antibody (mAb) with functional FcR binding, reverses TIGITCD155-mediated T-cell inhibition in preclinical models. ARC-12 will assess if AB308-mediated TIGIT pathway blockade augments zimberelimab (zim; anti-PD-1 mAb) activity.